{
  "docId": "019dd923-622b-71dc-a6d9-fc4318e06f9b",
  "docSlug": "6ded4b1cfe2c",
  "documentTitle": "Bristol-Myers Squibb Company (BMY)",
  "authorId": "03_Starboard_Value",
  "authorName": "Starboard Value",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "activist_investor",
  "sourceTypeLabel": "Activist investor",
  "presentationDate": "2019-03-18 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 25,
  "pageCount": 197,
  "prevPage": 24,
  "nextPage": 26,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "dense",
  "nDataPoints": 28,
  "notes": "Uses color-coding (red/yellow/green) to categorize product status.",
  "elementsJson": [
    "headline_text",
    "paragraph",
    "data_table",
    "callout_box",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622b-71dc-a6d9-fc4318e06f9b/25",
  "deckHref": "/decks/019dd923-622b-71dc-a6d9-fc4318e06f9b",
  "deckJsonHref": "/decks/019dd923-622b-71dc-a6d9-fc4318e06f9b.json",
  "deckAnchorHref": "/decks/019dd923-622b-71dc-a6d9-fc4318e06f9b#slide-25",
  "components": [
    {
      "bbox": {
        "h": 0.12,
        "w": 0.29,
        "x": 0.67,
        "y": 0.56
      },
      "kind": "callout",
      "text": "~55% of total drugs highlighted have been delayed, and peak sales potential has declined by greater than $4 billion (~40% discount)",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1c6588a7-6508-4cb5-8b73-a569f120a47b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.29,
        "x": 0.67,
        "y": 0.36
      },
      "kind": "callout",
      "text": "~30% of total drugs highlighted and greater than $5.5 billion of peak sales has been terminated or de-prioritized",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "57f250c1-ba2b-41f3-8b51-6eb8643b15ae",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "peak revenue potential: $5.5 billion",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd953-0936-7173-ab2d-57c5ab2bddf3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.92,
        "x": 0.04,
        "y": 0.12
      },
      "kind": "paragraph",
      "text": "Since Celgene management first highlighted fourteen significant products to their shareholders only two years ago, nearly one third of those products have already been terminated or de-prioritized, which represents greater than $5.5 billion of previously stated peak revenues.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e8401b65-aed1-43a0-9884-07e99f4282b5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.35,
        "x": 0.04,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "Source: Public company filings, Wall Street research, Starboard estimates.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "72c8542f-79c3-4365-b792-67a79d3720de",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.62,
        "w": 0.62,
        "x": 0.04,
        "y": 0.22
      },
      "kind": "table",
      "text": "Table showing 14 drugs, their status, Celgene stated peak revenue, and current Wall Street estimates.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9732685d-2238-4332-af93-713fabc78bbb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.92,
        "x": 0.04,
        "y": 0.86
      },
      "kind": "title",
      "text": "Celgene has a history of being overly optimistic and Bristol-Myers is not only paying up for these lofty expectations, but actually expecting even more",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "af4c4809-061d-470a-a001-bece06755f10",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.92,
        "x": 0.04,
        "y": 0.03
      },
      "kind": "title",
      "text": "Despite Celgene’s Disappointing Track Record of Failures and Product Delays...",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "212e28af-0a08-41b7-adfc-d0cb0ce84ee1",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "fraud-exposure",
      "slug": null,
      "matchId": "bbb483be-9ca9-4e12-a04b-f5c8de5dd540",
      "evidence": "Exposing discrepancy between management projections and actual outcomes to argue against a merger valuation.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 25,
      "from": 23,
      "name": "Aha Moment",
      "slug": "03-aha-moment",
      "bestFor": "Data-heavy sections, research findings, analytical arguments",
      "matchId": "b49fb8db-b8ba-426d-87eb-23164ab4f187",
      "evidence": "The document reveals concerns about Celgene's pipeline and its ability to meet Bristol-Myers' expectations.",
      "position": 0,
      "objective": "Highlighting the risks of Celgene's pipeline",
      "structure": "The Problem/Question -> What the Data Shows -> The Insight",
      "confidence": 0.7,
      "description": "Establish a tension, present data, then deliver the insight that changes everything"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}